Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback